|
|
 |
 Autoimmune
Technologies and Tulane University School of Medicine
are working to develop entry-inhibiting influenza drugs
based on small peptides. In the in vitro assays
run to date, our lead flu peptide drug, FF-3, appears to
be extremely effective against subtypes of the influenza
A virus which cause seasonal flu as well as against the
dangerous H5N1 influenza A subtype. It is also highly
effective against influenza B. In initial in vivo
tests, FF-3 demonstrated the ability
to completely eliminate all signs of seasonal influenza
A in most of the animals tested and to block transmission
of this seasonal flu among infected animals and their
uninfected cagemates.
|
| This material is not intended to take
the place of a physician's advice. |
|
 |
|
